From 2015 To 2026: Why Did It Take Eleven Years For Snapdeal’s Prescription Drug Case To Reach The Supreme Court?
In 2015, India's e-commerce revolution was only beginning. Online shopping was still earning consumers' trust, digital payments remained a work in progress and companies like Snapdeal were helping define a new era of retail. Eleven years later, one legal dispute from that period has finally reached the Supreme Court. But this is no longer just about an alleged online sale of a prescription medicine. It is about whether laws written decades before the internet can effectively regulate digital marketplaces that have transformed the way India shops.

More than a decade after Karnataka’s drug regulators alleged that a prescription medicine was sold through Snapdeal’s online marketplace without the safeguards required under law, the Supreme Court has agreed to examine a question that could have implications far beyond one company.
The apex court has issued notice to Snapdeal while hearing the Karnataka government’s appeal against a 2022 Karnataka High Court judgment that quashed criminal proceedings against the company and its founders.
At the heart of the dispute lies an alleged online purchase of Suhagra-100, a prescription medicine containing sildenafil, which investigators claimed was delivered without the buyer being asked to produce a valid doctor’s prescription.
According to Karnataka’s Drugs Control Department, the transaction violated provisions of the Drugs and Cosmetics Act, 1940, legislation that regulates the manufacture, sale and distribution of medicines in India. Investigators argued that allowing a prescription drug to be purchased online without the statutory safeguards raised serious public health concerns and warranted criminal prosecution.
Snapdeal has consistently rejected that interpretation.
The company maintains that it neither manufactured nor sold medicines and did not operate as a licensed pharmacy. Instead, it functioned as an online marketplace connecting independent sellers with buyers. Since the products were listed and sold by third-party vendors, Snapdeal argued that any liability should rest with those sellers rather than the platform itself.
The Karnataka High Court accepted that argument in 2022, quashing the criminal proceedings on the ground that the company functioned as an intermediary and that the allegations did not establish its direct involvement in the alleged sale.
The Karnataka government has now challenged that decision before the Supreme Court, arguing that the High Court interpreted the law too narrowly. By agreeing to hear the appeal, the Supreme Court is not deciding whether Snapdeal is guilty. Instead, it will examine whether an online marketplace can avoid criminal liability simply because the transaction was carried out by an independent seller using its platform.
That legal question extends well beyond pharmaceuticals.
The Court’s eventual ruling could influence how responsibility is determined across India’s rapidly expanding digital economy, affecting not only e-commerce platforms but potentially every online marketplace that enables third-party sellers to transact with consumers.
Yet another question deserves equal attention.
Why has it taken eleven years for a dispute arising from a single online transaction to reach the country’s highest court?
The answer reveals as much about India’s judicial system as it does about the country’s digital economy.

How One Online Order Turned Into An Eleven-Year Court Battle
The dispute now before the Supreme Court began not with a sweeping regulatory crackdown or a major corporate investigation, but with a single online purchase.
In 2015, officials from Karnataka’s Drugs Control Department launched an investigation into the online sale of prescription medicines. Their concern was straightforward: were consumers able to buy regulated drugs over the internet without complying with the safeguards laid down under the Drugs and Cosmetics Act, 1940?
To test that suspicion, drug inspectors allegedly placed an order for Suhagra-100, a Schedule H prescription medicine containing sildenafil, through Snapdeal’s marketplace. According to Karnataka’s prosecution, the medicine was delivered without the purchaser being required to produce a valid prescription from a registered medical practitioner.
For the regulators, that transaction demonstrated a potentially serious regulatory failure.
Prescription medicines are classified differently from ordinary consumer goods because their misuse can have significant health consequences. The law therefore requires stricter controls over how such medicines are sold and dispensed. Karnataka’s Drugs Control Department argued that if prescription drugs could be purchased online without these safeguards, it would undermine the regulatory framework designed to protect public health.
Based on the alleged transaction, the Drug Inspector initiated criminal proceedings before a Bengaluru trial court against Snapdeal, certain company officials and others associated with the sale. The complaint invoked provisions of the Drugs and Cosmetics Act relating to the sale and distribution of medicines without the necessary statutory compliance.
Snapdeal, however, viewed the matter through an entirely different legal lens.
The company maintained that it neither owned nor stocked the medicine in question. It did not operate a pharmacy, issue prescriptions or dispatch pharmaceutical products. Instead, it described itself as an intermediary marketplace that provided a digital platform where independent sellers could list products and consumers could purchase them.
In essence, Snapdeal argued that it functioned much like a shopping mall. The mall provides space for businesses to operate, but responsibility for the products sold rests with the individual retailers, not with the owner of the building itself.
According to the company, holding an online marketplace criminally liable for every product listed by thousands of independent vendors would fundamentally alter the intermediary model on which modern e-commerce operates. Unless a platform directly participated in or knowingly facilitated an unlawful transaction, responsibility, it argued, should remain with the seller.
Karnataka’s regulators disagreed.
They argued that digital marketplaces are not merely passive websites displaying advertisements. By enabling listings, connecting buyers and sellers, processing transactions and facilitating online commerce, platforms play a central role in making such sales possible. In their view, that role could not automatically shield them from liability when regulated products were allegedly sold in violation of the law.
The disagreement quickly evolved beyond the alleged sale of a single strip of tablets.
What began as an investigation into a prescription medicine ultimately became a test of a much larger legal principle: when does an online marketplace remain a neutral intermediary, and when does it become responsible for transactions carried out through its platform?
That question would eventually travel from a Bengaluru trial court to the Karnataka High Court and now, after more than a decade, to the Supreme Court.
Almost.



/theprobe/media/media_files/2026/06/24/judiciary-pending-cases-cag-looks-away-2026-06-24-14-28-19.jpg)





